Free tool
FAERS Monitor: Fycompa
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 208277 or its brand name (Fycompa, Perampanel). Reports on generic versions are filed under their own applications.
Reports
7,728
Serious
6,392
83% of reports
Hospitalization
2,965
Death reported
472
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- seizure1,171
- drug ineffective1,129
- off label use830
- somnolence525
- aggression504
- dizziness408
- epilepsy377
- status epilepticus350
- drug interaction343
- multiple-drug resistance332
- fatigue316
- irritability253
- condition aggravated247
- fall244
- gait disturbance226
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2012 | 8 |
| 2013 | 16 |
| 2014 | 183 |
| 2015 | 275 |
| 2016 | 332 |
| 2017 | 455 |
| 2018 | 572 |
| 2019 | 705 |
| 2020 | 664 |
| 2021 | 779 |
| 2022 | 668 |
| 2023 | 765 |
| 2024 | 908 |
| 2025 | 884 |
| 2026 | 514 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,046,431 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| multiple-drug resistanceSignal | 332 | 326.2 | 291.7 | 95,841 |
| status epilepticusSignal | 350 | 87.0 | 78.4 | 28,776 |
| epilepsySignal | 377 | 34.0 | 30.8 | 11,899 |
| seizureSignal | 1,171 | 27.9 | 26.4 | 30,161 |
| aggressionSignal | 504 | 27.7 | 25.4 | 12,833 |
| irritabilitySignal | 253 | 11.5 | 10.2 | 2,411 |
| somnolenceSignal | 525 | 7.1 | 6.5 | 2,771 |
| drug interactionSignal | 343 | 5.9 | 5.3 | 1,397 |
| gait disturbanceSignal | 226 | 3.2 | 2.8 | 346 |
| off label useSignal | 830 | 2.6 | 2.4 | 837 |
| drug ineffectiveSignal | 1,129 | 2.3 | 2.2 | 915 |
| dizzinessSignal | 408 | 2.2 | 2.0 | 281 |
| condition aggravatedSignal | 247 | 2.2 | 2.0 | 165 |
| fall | 244 | 2.0 | 1.8 | 122 |
| fatigue | 316 | 1.1 | 1.0 | 3 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.